Zydus Lifesciences gets final approval from USFDA for Dexamethasone Tablets

11 May 2024 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to market Dexamethasone Tablets USP, 1 mg (USRLD: Dexamethasone Tablets).

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer and immune system disorders. The product will be manufactured at the group’s formulation manufacturing facility at Baddi, Himachal Pradesh.

Dexamethasone Tablets USP, 1 mg had annual sales of $1.8 million in the United States (IQVIA MAT March 24). The group now has 395 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.


Zydus Lifesciences Share Price

909.90 -4.75 (-0.52%)
01-Jan-2026 10:11 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1713.60
Dr. Reddys Lab 1255.15
Cipla 1504.35
Zydus Lifesciences 909.90
Lupin 2086.40
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×